Chemical engineering

MIT researchers are developing targeted drug delivery through the use of nanoparticles to aid in cancer treatment, reports Simone Migliori for Boston Magazine. “Designed to circulate through the bloodstream, these small but mighty travelers [nanoparticles] can deliver a chemotherapy drug directly to a target cancer cell without disturbing any healthy cells along the way,” writes Migliori. “In doing so, patients may be able to avoid some of the worst side effects of chemotherapy drugs while still effectively treating their cancer.”

Natalia Rodriguez ’09 speaks with Diverse Issues in Higher Education reporter Pearl Stewart about her work as a biomedical engineer focused on community healthcare. “I work to bring health technologies from the lab to the people, and I also work to bring the needs, the priorities and the strengths of communities back to engineers so they know who they’re designing for,” Rodriguez explains. 

Deepak Dugar MBA ’13, PhD ’13 founded Visolis, a biomanufacturing company developing carbon-negative, high-performance materials, reports John Cumbers for Forbes. “We use biology to make platform molecules. And then we use chemistry to turn them into a lot of different products. Because of this unique combination, we have an advantage both in terms of market as well as cost of technology development,” says Dugar.

Forbes reporter John Cumbers spotlights Jasmina Aganovic ’09 for her work in combining biotechnology with skincare. "Biotechnology enables us to expand the ingredient palette of the beauty industry to molecules in all parts of the tree of life, ethically and sustainably," says Aganovic.

Landmark Bio, a cell and gene therapy manufacturing company co-founded by MIT and a number of other institutions, is focused on accelerating access to innovative therapies for patients, reports Rowan Walrath for Boston Business Journal. "Landmark's new facility includes laboratory space for research and early-stage drug development, as well as analytics tools,” writes Walrath. 

MIT and a number of other local institutions have launched Landmark Bio, a cell and gene therapy manufacturing firm aimed at helping small startups develop experimental therapies that are reliable, consistent, and large enough to be used in clinical trials, reports Ryan Cross for The Boston Globe.

Alumna Yue Chen has been named the chief climate risk office for the Office of the Comptroller of the Currency, reports Emily Flitter for The New York Times. “Dr. Chen will focus on developing a new system to assess climate-driven risks to banks, and figure out how to monitor and manage them,” says the agency.

Institute Professor Robert Langer has been honored as one of the recipients of this year’s Balzan Prize for his “pioneering research and advances in mRNA vaccines and tissue engineering,” the Associated Press reports. Langer has paved the way “for breakthroughs in the controlled release of macromolecules with many medical applications,” the Balzan Foundation noted in its citation.

Doctoral research specialist Morteza Sarmadi speaks with Emily Henderson from News Medical Life Sciences about his work with Prof. Robert Langer and research scientist Ana Jaklenec in developing microparticles that are able to deliver self-boosting vaccines. “We believe this technique can significantly reduce the need to visit a healthcare provider to receive booster shots, a major challenge in remote areas without sophisticated healthcare resources,” says Sarmadi.

Prof. Ariel Furst, and alumna Claire Beskin and Loewen Cavill were named the winners of the first annual MIT Female Founders Pitch, reports Stephanie MacConnell for Forbes. Furst’s company, Pharmor, has developed an inexpensive protective coating that allows microbes to be produced and transported in non-ideal conditions. Beskin’s company, Empallo, uses machine learning to unlock information on siloed patient data. And Cavill’s company, AuraBlue, has developed a wearable device that can predict hot flashes and enable a cooling pad to counteract the change in body temperature in menopausal women.

Lita Nelsen BS ’64, MS ’66, MBA ’79 writes for The Boston Herald about the Bayh-Dole Act, a landmark piece of legislation that allows universities to keep the patents to their own inventions. “As the head of MIT’s Technology Licensing Office for almost three decades, I helped license thousands of technologies to the innovative companies that sprung up around campus,” writes Nelsen. “The Bayh-Dole Act has indisputably helped the U.S. life sciences sector become the envy of the world.”

Nature reporter Neil Savage spotlights Prof. Michael Strano’s work developing a new technique to use nanoparticles to alter the biology of living plants. Savage writes that the new technique can allow for "the design of nanoparticles that carry gene-editing machinery to targeted areas to rewrite the plant’s genome and imbue it with properties such as pest and disease resistance,” writes Savage.

Prof. Yoel Fink speaks with Washington Post reporter Pranshu Verma about the growing field of smart textiles and his work creating fabrics embedded with computational power. Fink and his colleagues “have created fibers with hundreds of silicon microchips to transmit digital signals — essential if clothes are to automatically track things like heart rate or foot swelling. These fibers are small enough to pass through a needle that can be sown into fabric and washed at least 10 times.”

Scientists at MIT are developing a self-boosting vaccine that can provide multiple doses of a vaccine via a single injection, reports Darko Manevski for Newsweek. The technology “could be particularly useful for administering childhood vaccinations in regions where people do not have regular access to medical care,” writes Manevski.

MIT scientists are developing self-boosting vaccine technology that could allow people to receive all of their vaccine doses in one shot, reports The Economist. This technology “would be a game-changer, not only for future pandemics but also for vaccination programs in remote regions where it is harder to deliver boosters,” The Economist notes.